A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocar...

Por Li, D., Pant, S., Ryan, D.P., Laheru, D., Bahary, N., Dragovich, T., Hosein, P.J., Rolfe, L., Saif, M.W., LaValle, J., Yu, K.H., Lowery, M.A., Allen, A., O'Reilly, E.M.
Publicado no Pancreatology (2014)